Cargando…
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
Epcoritamab is a CD3xCD20 bispecific antibody (bsAb) that induces T‐cell–mediated cytotoxicity against CD20‐positive B cells. Target engagement and crosslinking of CD3 and CD20 (trimer formation) leads to activation and expansion of T cells and killing of malignant B cells. The primary objective of...
Autores principales: | Li, Tommy, Hiemstra, Ida H., Chiu, Christopher, Oliveri, Roberto S., Elliott, Brian, DeMarco, Dena, Salcedo, Theodora, Egerod, Frederikke Lihme, Sasser, Kate, Ahmadi, Tahamtan, Gupta, Manish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827893/ https://www.ncbi.nlm.nih.gov/pubmed/35996883 http://dx.doi.org/10.1002/cpt.2729 |
Ejemplares similares
-
Semimechanistic pharmacokinetic–pharmacodynamic model of tripegfilgrastim for pediatric patients after chemotherapy
por: Lee, Soyoung, et al.
Publicado: (2023) -
A semimechanistic population pharmacokinetic and pharmacodynamic model incorporating autoinduction for the dose justification of TAS‐114
por: Araki, Hikari, et al.
Publicado: (2021) -
Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria
por: Wattanakul, Thanaporn, et al.
Publicado: (2021) -
Quantitative Pharmacodynamic Characterization of Resistance versus Heteroresistance of Colistin in E. coli Using a Semimechanistic Modeling of Killing Curves
por: Mead, Andrew, et al.
Publicado: (2022) -
Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting
por: Mhibik, Maissa, et al.
Publicado: (2023)